Company Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-14 pm EDT 5-day change 1st Jan Change
10.14 USD -4.74% Intraday chart for Amicus Therapeutics, Inc. +0.90% -28.54%

Business Summary

Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

Number of employees: 517

Sales per Business

USD in Million2022Weight2023Weight Delta
Advanced Therapies
100.0 %
329 100.0 % 399 100.0 % +21.30%

Sales per region

USD in Million2022Weight2023Weight Delta
Non-United States
63.2 %
213 64.8 % 252 63.2 % +18.35%
United States
36.8 %
116 35.2 % 147 36.8 % +26.73%

Managers

Managers TitleAgeSince
Chief Executive Officer 48 06-03-31
Director of Finance/CFO 63 23-08-20
Chief Operating Officer - 22-06-30
Chief Tech/Sci/R&D Officer - 19-12-31
Chief Tech/Sci/R&D Officer - 19-06-12
Compliance Officer - 15-07-31
Investor Relations Contact - -
Corporate Officer/Principal - Oct. 31
Human Resources Officer 49 18-09-30
Comptroller/Controller/Auditor 46 18-02-28

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 48 06-03-31
Director/Board Member 60 18-09-10
Director/Board Member 68 19-06-26
Director/Board Member 64 09-09-30
Director/Board Member 67 20-11-30
Director/Board Member 68 06-05-31
Director/Board Member 63 16-06-09
Chairman 59 04-04-30
Director/Board Member 60 21-06-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 296,198,963 265,920,799 ( 89.78 %) 0 89.78 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.522 %
28,204,309 9.522 % 276 M $
Perceptive Advisors LLC
9.473 %
28,057,456 9.473 % 275 M $
Avoro Capital Advisor LLC
9.251 %
27,400,000 9.251 % 269 M $
BlackRock Advisors LLC
7.305 %
21,638,099 7.305 % 212 M $
Wellington Management Co. LLP
6.348 %
18,803,645 6.348 % 184 M $
JPMorgan Investment Management, Inc.
5.298 %
15,691,157 5.298 % 154 M $
Janus Henderson Investors US LLC
4.664 %
13,814,514 4.664 % 135 M $
Redmile Group LLC
4.476 %
13,257,286 4.476 % 130 M $
12,442,501 4.201 % 122 M $
William Blair Investment Management LLC
3.891 %
11,526,279 3.891 % 113 M $

Company contact information

Amicus Therapeutics, Inc.

47 Hulfish Street

08542, Princeton

+609 662 2000

http://www.amicusrx.com
address Amicus Therapeutics, Inc.(FOLD)
  1. Stock Market
  2. Equities
  3. FOLD Stock
  4. Company Amicus Therapeutics, Inc.